Drug Type Small molecule drug |
Synonyms ((1R,3S)-1-Amino-3-((S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol, Udifitimod Hydrochloride, BMS 986166 + [2] |
Target |
Mechanism S1PRs modulators(Sphingosine 1-phosphate receptor modulators) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H33NO2 |
InChIKeyQCMHGCDOZLWPOT-FMNCTDSISA-N |
CAS Registry1883345-06-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dermatitis, Atopic | Phase 2 | US | 17 Aug 2021 | |
Dermatitis, Atopic | Phase 2 | AU | 17 Aug 2021 | |
Dermatitis, Atopic | Phase 2 | AT | 17 Aug 2021 | |
Dermatitis, Atopic | Phase 2 | CA | 17 Aug 2021 | |
Dermatitis, Atopic | Phase 2 | DE | 17 Aug 2021 | |
Dermatitis, Atopic | Phase 2 | PL | 17 Aug 2021 | |
Dermatitis, Atopic | Phase 2 | ES | 17 Aug 2021 | |
Colitis, Ulcerative | Phase 1 | US | 01 Feb 2017 |
Phase 2 | 17 | Placebo | aevvujxxtb(fumxbtlwiy) = reqodabjen sectofycfb (qhswlsordl, dezspfswzu - xlhbixxozd) View more | - | 18 Oct 2023 |